Sheppard Mullin represented RadNet, and Latham & Watkins represented the underwriters. RadNet, Inc. (NASDAQ: RDNT) has announced the closing of its underwritten public offering of 8,711,250 shares...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Alpha II and existing shareholder WestView Capital Partners on TA Associates strategic Growth investment. TA Associates, a leading global private equity firm,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
You must be a Standard 1 Year member to access this content.
Advestra and Latham & Watkins advise Ironwood. Homburger AG serves as legal and tax advisor to VectivBio on the transaction. Goodwin advises Centerview Partners. VectivBio Holding...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Oaktree on the financing. Harrow (Nasdaq: HROW) announced that it has entered into a $100 million secured credit financing agreement with funds...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
